DCT

1:26-cv-01013

Hetero Labs Ltd v. Otsuka America Pharmaceutical Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-01013, D. Del., 08/10/2026
  • Venue Allegations: Venue is alleged to be proper as Defendants are Delaware corporations that have purposefully availed themselves of the forum by previously filing patent enforcement actions in the district.
  • Core Dispute: Plaintiff seeks a declaratory judgment that Defendant's patent related to the drug NUEDEXTA® is invalid, unenforceable, and not infringed by Plaintiff's generic equivalent, and further alleges that Defendant's enforcement of the patent constitutes unlawful monopolization.
  • Technical Context: The technology concerns a combination pharmaceutical therapy using dextromethorphan and a low dose of quinidine to treat pseudobulbar affect (PBA), a neurological condition causing involuntary emotional expressions.
  • Key Procedural History: This declaratory judgment action follows prior litigation in which Defendants obtained a preliminary injunction preventing Plaintiff from launching its generic product. The Federal Circuit affirmed the injunction but vacated the district court's waiver of a security bond, remanding the issue. The complaint heavily references the patent's prosecution history, alleging the patent was obtained through misrepresentations to the U.S. Patent and Trademark Office regarding the claimed invention's support in the original disclosure.

Case Timeline

Date Event
2002-07-17 '282 Patent Priority Date
2005-01-12 '282 Patent Application Filing Date
2009-01-09 Patent Examiner issues Final Office Action rejecting claims
2009-07-07 Patentee (Avanir) responds to Office Action, amending claims
2010-02-09 '282 Patent Issue Date
2010-10-01 FDA approves NUEDEXTA® (branded drug)
2011-01-01 Marketing begins for NUEDEXTA®
2024-08-28 FDA approves Plaintiff's (Hetero's) generic ANDA Product
2025-05-22 Hetero informs Otsuka of intent to launch generic product
2025-05-27 Otsuka sues Hetero for patent infringement
2025-07-23 Preliminary Injunction granted, preventing Hetero's launch
2026-07-01 Federal Circuit affirms injunction but remands on bond issue
2026-08-10 Complaint Filing Date
2026-08-13 '282 Patent Expiration Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,659,282 - "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders"

  • Issued: February 9, 2010

The Invention Explained

  • Problem Addressed: The patent addresses the need for an effective treatment for neurological disorders such as pseudobulbar affect (PBA) and emotional lability, which are characterized by involuntary, disruptive episodes of laughing or crying '282 Patent, col. 1:21-39 The patent also notes that while dextromethorphan (DM) has therapeutic potential, its rapid metabolism in the body limits its effectiveness '282 Patent, col. 11:41-49
  • The Patented Solution: The invention is a method of administering DM in combination with a low dose of quinidine '282 Patent, abstract The quinidine serves as an inhibitor of the CYP2D6 enzyme, which is responsible for metabolizing DM '282 Patent, col. 12:5-13 By inhibiting this enzyme, the quinidine increases the bioavailability and plasma concentration of DM, allowing it to be therapeutically effective at a lower, safer dose '282 Patent, col. 12:5-13 '282 Patent, col. 19:10-20
  • Technical Importance: This approach provided a way to achieve the therapeutic benefits of dextromethorphan while using a sub-therapeutic dose of quinidine, thereby avoiding the known safety and tolerability issues associated with higher, cardio-active doses of quinidine '282 Patent, col. 6:22-26

Key Claims at a Glance

  • The complaint asserts that claims of the '282 Patent are invalid, unenforceable, and not infringed, focusing on the limitations of independent claim 1 Compl. ¶47 Compl. ¶50
  • The essential elements of independent claim 1 are:
    • A method of treating pseudobulbar affect or emotional lability by administering a combination of dextromethorphan and quinidine.
    • The drugs are in a combined dose form.
    • The dextromethorphan amount is from about 20 mg/day to about 80 mg/day.
    • The quinidine amount is from about 10 mg/day to less than about 30 mg/day.
    • The weight-to-weight ratio of dextromethorphan to quinidine is 1:0.5 or less.
  • The complaint challenges the "asserted claims" generally, suggesting other dependent or independent claims may be at issue Compl. ¶46

III. The Accused Instrumentality

Product Identification

  • The product at issue is "Hetero's ANDA Product," an Abbreviated New Drug Application product intended as a generic version of NUEDEXTA® Compl. ¶2

Functionality and Market Context

  • The product is a capsule formulation containing 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate Compl. ¶2
  • The complaint alleges that Hetero's product is a lower-priced generic that would compete directly with NUEDEXTA®, which Defendants have allegedly stated is the "first and only FDA-approved treatment for PBA on the market" Compl. ¶113 Compl. ¶114 The introduction of this generic competition is alleged to create downward economic pressure on the branded drug's price Compl. ¶119 Compl. ¶125

IV. Analysis of Infringement Allegations

The complaint is a declaratory judgment action seeking a declaration of non-infringement, invalidity, and unenforceability. It does not contain a detailed, element-by-element infringement analysis or claim chart. Instead, it makes a general denial that its ANDA product infringes any valid and enforceable claim of the '282 Patent Compl. ¶100 The core of the complaint's technical argument is focused on invalidity for lack of written description and enablement, and unenforceability for inequitable conduct.

No probative visual evidence provided in complaint.

  • Identified Points of Contention:
    The primary contentions in the complaint relate to patent validity and enforceability, which in turn define the scope of the claims for any infringement analysis.
    • Scope Questions: A central dispute is whether the combination of limitations recited in the asserted claims was possessed by the inventors at the time of filing. The complaint raises the question of whether the claimed therapeutic regimen-specifically the combination of the dextromethorphan dose range, the low quinidine dose range, and the specific weight-to-weight ratio-is adequately described in the patent's specification for the treatment of PBA Compl. ¶48 Compl. ¶79 Hetero alleges it can only be arrived at through retrospective "cobbling together" of disparate disclosures Compl. ¶50
    • Technical Questions: The complaint questions whether the patent's disclosed clinical data supports the claimed invention. It alleges that the single PBA efficacy study described in the patent used dosages (60 mg/day DM and 60 mg/day quinidine) and a ratio (1:1) that fall outside the limitations of the asserted claims Compl. ¶¶69-71 This raises the question of what evidence, if any, the specification provides to demonstrate the efficacy of the specific regimen that was ultimately claimed.

V. Key Claim Terms for Construction

The complaint's invalidity and unenforceability arguments suggest that the construction and, more critically, the written description support for the following claim limitations will be central to the dispute.

  • The Term: "approximately 10 mg/day to less than about 30 mg/day quinidine"

    • Context and Importance: This quinidine dosage range was added during prosecution to overcome an obviousness rejection Compl. ¶21 Compl. ¶29 Hetero alleges this range was not part of the original invention but was a "later discovery" made after FDA feedback required a dose reduction Compl. ¶49 Compl. ¶78 Practitioners may focus on this term because its validity under 35 U.S.C. § 112 appears to be a primary basis for Hetero's invalidity and inequitable conduct claims.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: During prosecution, the patentee represented that the amended quinidine range found support in original claim 9 Compl. ¶23 Compl. ¶50
      • Evidence for a Narrower Interpretation: The complaint alleges that original claim 9 recited a different range of approximately 30-60 mg/day quinidine, with 30 mg/day as its lower endpoint, not its upper boundary Compl. ¶60 Compl. ¶62 It further alleges that the only PBA efficacy study in the specification used 60 mg/day of quinidine, well outside the claimed range Compl. ¶70 Compl. ¶71

  • The Term: "the weight ratio of dextromethorphan to quinidine is 1:0.5 or less"

    • Context and Importance: This ratio was also added during prosecution and is a key limitation distinguishing the claimed invention from prior art Compl. ¶21 Compl. ¶22 Hetero's challenge focuses on whether this ratio was disclosed in combination with the claimed dosage ranges for treating PBA.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent specification lists numerous possible weight ratios, including "about 1:0.5" '282 Patent, col. 16:27 The patentee represented to the USPTO that this ratio was "expressly recited" Compl. ¶23
      • Evidence for a Narrower Interpretation: The complaint alleges that the specification does not disclose this ratio in combination with the claimed dosage ranges as a defined therapeutic regimen for PBA Compl. ¶54 The PBA efficacy study detailed in the patent specification allegedly used a 1:1 ratio, which is not "1:0.5 or less" Compl. ¶70 Compl. ¶71

VI. Other Allegations

  • Inequitable Conduct: The complaint contains a detailed claim for unenforceability due to inequitable conduct Compl. ¶¶82-97 It alleges that the patentee's attorney, with intent to deceive, misrepresented to the patent office that the amended claims were expressly supported by the specification Compl. ¶87 At the same time, the attorney allegedly withheld material information showing the inventors did not possess the full scope of the invention as of the filing date, including an inventor's declaration describing the effective low-dose quinidine regimen as a "later discovery" Compl. ¶84 Compl. ¶90 Compl. ¶91

  • Walker Process Fraud (Antitrust): The complaint alleges monopolization in violation of Section 2 of the Sherman Act, based on a Walker Process theory Compl. ¶¶102-137 This claim asserts that the '282 Patent was procured through "knowing and willful fraud" (the same conduct underlying the inequitable conduct claim) and that Defendants subsequently enforced the patent via litigation to unlawfully maintain monopoly power and exclude generic competition from Hetero Compl. ¶103 Compl. ¶111

VII. Analyst's Conclusion: Key Questions for the Case

  1. A core issue will be one of patent validity: Does the original patent disclosure provide adequate written description to support the specific combination of dosage ranges and the drug ratio that was added to the claims during prosecution? The court will need to determine if, as Hetero alleges, this combination was a "later discovery" that cannot claim the benefit of the original filing date.

  2. A second key issue will be patent enforceability: Did the patentee's representatives engage in inequitable conduct by making material misrepresentations to the USPTO regarding specification support for the amended claims while simultaneously possessing and failing to disclose contrary evidence, such as the inventor's own declaration?

  3. A third, contingent issue will be one of antitrust liability: If the patent is found to have been procured by fraud, the court will then examine whether the Defendants' enforcement of that patent against Hetero constituted an illegal act of monopolization that caused Hetero a direct antitrust injury.

Loading Complaint